ABAna Filipa Bizarro

Ana Filipa Bizarro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Filipa Bizarro has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Potential of Cannabidiol for Treating Canine Atopic Dermatitis

    by Ana F. Bizarro, Vanessa M. Schmidt, Beatriz Fernandes, Marta Pinto, Hugo Pereira, Joana Marto, Ana M. Lourenço

    Atopic dermatitis is prevalent in humans (hAD) and dogs (cAD) and profoundly impacts the patients’ quality of life. The increasing number of new drugs in development for atopic dermatitis indicates both the need and potential for precision medicine to generate an optimised benefit–risk therapeutic plan. Cannabidiol (CBD), known for its potential anti-inflammatory and antipruritic properties, shows promise in hAD and cAD management, prompting the exploration of cannabinoids (CBs) and CBD as therapeutic tools. In fact, encouraging results on the benefits of using CBD in cAD have been published, along with safety evaluations that reveal that CBD is generally well tolerated in dogs. However, limited placebo-controlled trials and dosage variations in dogs pose barriers that hinder definitive conclusions. Challenges in product stability, inconsistent formulations, and legal ambiguities highlight the need for standardised CBD-based products for both research and commercial uses. The complex legal landscape further complicates accessibility and regulation. Despite these challenges, CBD is emerging as a potential avenue for cAD management, urging further high-quality research, standardised formulations, and legal clarity. This brief review provides valuable insights into the therapeutic potential of CBs and CBD in cAD, compared to hAD, emphasising the importance of rigorous research and unambiguous regulation for successful integration into veterinary dermatology.


  • Challenging the norm: Epicutaneous immunotherapy for canine atopic dermatitis

    by Marta Sofia das Neves Pinto, Solange Judite Roque Coelho Alves Gil, Laura Ramió‐Lluch, Vanessa Merta Schmidt, Hugo Miguel Lino Pereira, Beatriz Amaral Pinto Fernandes, Ana Filipa Bizarro Camões, Mário Morais‐Almeida, Berta Maria Fernandes Ferreira São Braz, Joana Marques Marto, et al.


  • Open Access

    Primary Prevention of Canine Atopic Dermatitis: Breaking the Cycle—A Narrative Review

    by Beatriz Fernandes, Susana Alves, Vanessa Schmidt, Ana Filipa Bizarro, Marta Pinto, Hugo Pereira, Joana Marto, Ana Mafalda Lourenço

    Canine atopic dermatitis (cAD) is a common and distressing skin condition in dogs, affecting up to 30% of the canine population. It not only impacts their quality of life but also that of their owners. Like human atopic dermatitis (hAD), cAD has a complex pathogenesis, including genetic and environmental factors. Current treatments focus on managing clinical signs, but they can be costly and have limitations. This article emphasizes the importance of preventing cAD from developing in the first place. Understanding the role of the skin’s protective barrier is crucial, as its dysfunction plays a vital role in both hAD and cAD. hAD prevention studies have shown promising results in enhancing the skin barrier, but more research is needed to support more robust conclusions. While hAD primary prevention is currently a focal point of intensive investigation in human medicine, research on cAD primary prevention remains under-researched and almost non-existent. Pioneering effective prevention strategies for cAD holds immense potential to enhance the quality of life for both dogs and their owners. Additionally, it bears the promise of a translational impact on human research. Hence, further exploration of this crucial topic is not only relevant but also timely and imperative, warranting support and encouragement.


  • Are images worth a thousand words? A preliminary study testing a video for owner education in canine atopic dermatitis

    by Beatriz Fernandes, Afonso Cavaco, Marta Pinto, Ana Filipa Bizarro, Hugo Pereira, Ana Mafalda Lourenço

    Background: Successful management of canine atopic dermatitis (cAD) is challenging and effective pet owner education is crucial to successful outcomes. However, there are limited proven educational strategies in this area. Our goal was to create an effective and engaging educational tool for owners of dogs with cAD.Hypothesis: Video‐based education efficacy would be comparable to traditional verbal delivery. Secondary objectives included assessing client perception of the intervention, and determining if there were clinical benefits for the dogs and improved client adherence to treatment.Subjects: Twenty‐nine dogs with cAD and their owners were recruited from a teaching hospital of a European veterinary medicine faculty.Materials and Methods: In this 8 week, prospective, randomised controlled study, clients in the control group (CG, n = 13) received verbal education and those in the intervention group (IG, n = 16) watched a video. Client knowledge was assessed at Day (D)0 and D56. Treatment adherence and perceived utility and appeal ratings were measured at D56. Clinical progress was assessed at D0 and D56 using CADESI‐04 and PVAS10.Results: The differences found in the means of cAD knowledge score, clinical outcomes, utility and appeal ratings and owners' adherence score between groups were not statistically significant. A significant association between the outcome and the intervention group concerning education success [CG, six of 13 (46.15%); IG, 15 of 16 (93.75%)] was found (p = 0.01).Conclusions and Clinical Relevance: Video‐based instructions positively impacted owners' education and demonstrated their potential as a valuable tool. The authors believe that video‐based education could be a time‐efficient alternative for initial cAD education in veterinary clinics.


  • Open Access

    Protocolo alternativo com oclacitinib para dermatite atópica canina: Uma solução capaz de reduzir custos?

    by Ana Bizarro, Anabela Martins, Marta Pinto, Beatriz Fernandes, Hugo Pereira, Berta Braz, Ana Lourenço

    Introdução: O oclacitinib é um inibidor seletivo da enzima cinase de Janus, que tem como alvo a interleucina-31, sendo utilizado no tratamento da dermatite atópica canina. Apesar de os tutores apresentarem um elevado grau de satisfação com este fármaco, o seu custo representa um foco de preocupação para 75%, sendo que 42,5% dos tutores referiram ter de limitar outras despesas para poderem pagar o tratamento do seu cão. Objetivos: Avaliar a possibilidade de adotar um protocolo alternativo com oclacitinib em dias alternados. Secundariamente, avaliar se existe vantagem em adicionar glucocorticoides orais no início deste protocolo. Métodos: Estudo prospetivo, aleatório, duplamente cego e controlado com placebo, incluindo 16 cães com diagnóstico de dermatite atópica, alocados nos grupos P (n=7; Placebo) e G (n=9; Glucocorticoides). Os animais foram avaliados quanto à gravidade lesional (CADESI-04) e grau de prurido (PVAS) no Dia -30, Dia 0 e end-point (recidiva ou Dia 30). O estudo comportou duas fases distintas e sucessivas. Na primeira fase foi administrado oclacitinib (0,4-0,6 mg/kg, 14 dias, duas vezes por dia [BID], depois 16 dias, uma vez por dia [SID]) por via oral a ambos os grupos. No entanto, nos primeiros 7 dias, ao grupo G foi administrada prednisolona (1mg/kg SID) por via oral e ao grupo P um placebo no mesmo regime. Na segunda fase, todos os animais realizaram o mesmo tratamento, mantendo o oclacitinib, mas apenas em dias alternados, até à recidiva do seu quadro clínico. Resultados: Foi possível adotar o protocolo em dias alternados durante pelo menos 30 dias em 71,43% dos animais. As diferenças encontradas não foram estatisticamente significativas entre as médias de CADESI-04 e grau de prurido dos dois grupos no Dia 0 e no end-point. Também não foram encontradas diferenças entre os períodos de tempo médios sob o tratamento em dias alternados. Conclusões: Existe potencial neste protocolo em dias alternados que permite reduzir os custos mensais para metade, possibilitando um maior acesso a esta ferramenta terapêutica inovadora, segura e muito eficaz, mas também dispendiosa. Não parece existir benefício, em termos de redução da dose de oclacitinib, na introdução de prednisolona no início do tratamento.


  • Efficacy and safety of lokivetmab (Cytopoint®) for the control of pruritus and skin lesions in dogs with atopic dermatitis

    by Marta Pinto, Maria Silva, Beatriz Fernandes, Ana Bizarro, Hugo Pereira, Ana Lourenço

    Background and objective: Lokivetmab is the first anti-canine interleukin-31 monoclonal antibody approved in the European Union for Canine Atopic Dermatitis (CAD) management. This study aimed to assess the lokivetmab’s efficacy and safety in treating CAD cases from a university reference service, as well as the dog’s owner’s overall opinion regarding therapy. Methods: Eighteen atopic dogs were enrolled to perform two subcutaneous injections of lokivetmab, according to the protocol. In order to determine the efficacy and safety of the treatment, skin lesions, pruritus score, blood count, liver parameters and adverse side effects were evaluated over 56 days. The overall pet owner’s satisfaction about the therapy was assessed at the end of the study, and the number of animals that maintained the treatment three months after the end of the study was considered. Results: There was a significant reduction in pruritus score over the eight weeks, with 76.5% of the dogs showing a significant clinical improvement. Regarding the lesion score, 77.8% of the dogs achieved significant clinical improvement, with 61.1% reaching it in the first 4 weeks. There were no reported adverse side effects or changes in blood tests. Pet owner’s opinion regarding the improvement of both the dog and its family’s quality of life was very positive, and three months after the end of the study, 77.8% of the dogs continued their therapy with lokivetmab. Conclusion: Lokivetmab proved to be extremely effective and safe, in addition to sparing pet owners from at home drug administrations, which also contributes to their high satisfaction degree. The great specificity of this biological therapy makes it one of the most potent and promising in the CAD field.